Sonnet BioTherapeutics Holdings Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Sonnet BioTherapeutics Holdings.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 26.8% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 20 Dec 2024 |
Recent future growth updates
Recent updates
Sonnet BioTherapeutics regains compliance with Nasdaq's minimum bid price requirement
Oct 04Sonnet BioTherapeutics announces 1-for-14 reverse stock split
Sep 16Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia
Jul 22We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate
Dec 19
Sonnet Bio issued U.S. patent for its albumin binding technology
Jun 08Sonnet shares rise after completing licensing agreement with New Life Therapeutics
May 03Sonnet BioTherapeutics reports FY results
Dec 17Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2025 | N/A | N/A | N/A | N/A | 1 |
| 9/30/2024 | 0 | -7 | -9 | -9 | N/A |
| 6/30/2024 | 0 | -8 | -10 | -10 | N/A |
| 3/31/2024 | 0 | -8 | -13 | -13 | N/A |
| 12/31/2023 | 0 | -14 | -19 | -19 | N/A |
| 9/30/2023 | 0 | -19 | -22 | -21 | N/A |
| 6/30/2023 | 0 | -23 | -23 | -23 | N/A |
| 3/31/2023 | 0 | -27 | -25 | -25 | N/A |
| 12/31/2022 | 0 | -29 | -26 | -26 | N/A |
| 9/30/2022 | 0 | -30 | -29 | -28 | N/A |
| 6/30/2022 | 1 | -29 | -28 | -27 | N/A |
| 3/31/2022 | 1 | -27 | -26 | -25 | N/A |
| 12/31/2021 | 1 | -25 | -26 | -26 | N/A |
| 9/30/2021 | 0 | -25 | -23 | -23 | N/A |
| 6/30/2021 | N/A | -67 | -22 | -22 | N/A |
| 3/31/2021 | N/A | -73 | -23 | -23 | N/A |
| 12/31/2020 | N/A | -69 | -19 | -19 | N/A |
| 9/30/2020 | N/A | -66 | -16 | -16 | N/A |
| 6/30/2020 | N/A | -20 | -11 | -11 | N/A |
| 3/31/2020 | N/A | -9 | -5 | -5 | N/A |
| 12/31/2019 | N/A | -7 | -4 | -4 | N/A |
| 9/30/2019 | N/A | -5 | -2 | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if SONN's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if SONN's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if SONN's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if SONN's revenue is forecast to grow faster than the US market.
High Growth Revenue: SONN is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SONN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 21:46 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sonnet BioTherapeutics Holdings, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Chardan Capital Markets, LLC |
| Michael King | H.C. Wainwright & Co. |